This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Oct 2018

New portable and ready-to-use upper respiratory drug delivery solution

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Aptar Pharma has released an industry first - PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

PureHale was officially launched this week at CPHI Worldwide in Madrid and was a finalist in the CPHI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.

With the ongoing rise in pollution the need for upper respiratory relief is more prominent than ever. PureHale’s innovative technology distributes a continuous fine mist that gently cleanses, moisturizes and soothes the upper respiratory tract, in turn helping to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.

PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Developed after researching and analysing the benefits and challenges of traditional nebulizer technology, this new user-friendly system was engineered for on-the-go consumers. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir.

The PureHale technology platform benefits include the following:

  • Use of non-electronic technology eliminates need to plug in or charge
  • Quieter and lighter than traditional nebulizers
  • Complete portability and always ready to use
  • Includes mask and mouthpiece options, offering adaptable treatment and suitable for family use
  • Continuous cooling mist with fine particles (20-30µm) optimized for targeted deposition to the upper airways.
  • Guenter Nadler, Director Business Development at Aptar Pharma, said: “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”

    Utilizing Aptar Pharma’s well-established Bag-on-Valve technology, the PureHale system preserves the integrity of the treatment solution while utilizing compressed air/nitrogen between the bag and can to create a continuous mist when actuated. This solution is valuable to pharmaceutical partners seeking a system that can carry a range of formulations, comes in various container sizes, while also offering differentiating and branding advantages.

    “PureHale enables pharmaceutical partners to expand their audience reach for their brand formulations, providing portable, symptomatic relief for upper respiratory system conditions,” said Thomas Klofac, President of Aptar Pharma’s Consumer Healthcare Division. PureHale provides brand differentiation via a range of personalization options and, with minimal parameter changes, existing filling processes can be easily adapted to fill PureHale. Aptar Pharma has extensive regulatory experience and this, combined with several standardized solutions, can satisfy a rapid-to-market launch objective.”

    Related News